GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huaren Pharmaceutical Co Ltd (SZSE:300110) » Definitions » Capex-to-Revenue

Huaren Pharmaceutical Co (SZSE:300110) Capex-to-Revenue : 0.09 (As of Mar. 2025)


View and export this data going back to 2010. Start your Free Trial

What is Huaren Pharmaceutical Co Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Huaren Pharmaceutical Co's Capital Expenditure for the three months ended in Mar. 2025 was ¥-25.82 Mil. Its Revenue for the three months ended in Mar. 2025 was ¥303.47 Mil.

Hence, Huaren Pharmaceutical Co's Capex-to-Revenue for the three months ended in Mar. 2025 was 0.09.


Huaren Pharmaceutical Co Capex-to-Revenue Historical Data

The historical data trend for Huaren Pharmaceutical Co's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huaren Pharmaceutical Co Capex-to-Revenue Chart

Huaren Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.02 0.03 0.03 0.02

Huaren Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.02 0.01 - 0.09

Competitive Comparison of Huaren Pharmaceutical Co's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Huaren Pharmaceutical Co's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Huaren Pharmaceutical Co's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Huaren Pharmaceutical Co's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Huaren Pharmaceutical Co's Capex-to-Revenue falls into.


;
;

Huaren Pharmaceutical Co Capex-to-Revenue Calculation

Huaren Pharmaceutical Co's Capex-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-24.694) / 1353.162
=0.02

Huaren Pharmaceutical Co's Capex-to-Revenue for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-25.822) / 303.472
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Huaren Pharmaceutical Co  (SZSE:300110) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Huaren Pharmaceutical Co Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Huaren Pharmaceutical Co's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Huaren Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 187 Zhuzhou Road, Qingdao, Shandong, CHN, 266100
Huaren Pharmaceutical Co Ltd is a China-based company engaged in the manufacture, and sale of non-polyvinyl chloride and Non-PVC large capacity preparations. Its categories of products include conventional infusion, therapy infusion, and nutrition infusion. The company distributes its products in domestic market, with Northeast China as its main market.
Executives
Yang Xiao Dong Director
Bo Guo Xiu Executives
Zhou Xi Jian Director
Mao Yu Wei Supervisors
Chu Xiao Jun Executives
Zhou Qiang Directors, executives
Ji Sheng Bin Executives
Xiao Wei Wen Executives
Shen Hong Ce Executives
Li Xiao Li Executives
Liu Qian Executives
Wang Wen Ping Executives
Liang Fu You Director
Liang Fu Dong Director
Gong Ling Secretary Dong

Huaren Pharmaceutical Co Headlines

No Headlines